Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics by Wilken, Jason A et al.
Wilken et al. Journal of Ovarian Research 2010, 3:7
http://www.ovarianresearch.com/content/3/1/7
Open Access RESEARCH
BioMed  Central
© 2010 Wilken et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research Trastuzumab Sensitizes Ovarian Cancer Cells to 
EGFR-targeted Therapeutics
Jason A Wilken1, Kristy T Webster2,3 and Nita J Maihle*1,4
Abstract
Background: Early studies have demonstrated comparable levels of HER2/ErbB2 expression in both breast and ovarian 
cancer. Trastuzumab (Herceptin), a therapeutic monoclonal antibody directed against HER2, is FDA-approved for the 
treatment of both early and late stage breast cancer. However, clinical studies of trastuzumab in epithelial ovarian 
cancer (EOC) patients have not met the same level of success. Surprisingly, however, no reports have examined either 
the basis for primary trastuzumab resistance in ovarian cancer or potential ways of salvaging trastuzumab as a potential 
ovarian cancer therapeutic.
Methods: An in vitro model of primary trastuzumab-resistant ovarian cancer was created by long-term culture of 
HER2-positive ovarian carcinoma-derived cell lines with trastuzumab. Trastuzumab treated vs. untreated parental cells 
were compared for HER receptor expression, trastuzumab sensitivity, and sensitivity to other HER-targeted 
therapeutics.
Results: In contrast to widely held assumptions, here we show that ovarian cancer cells that are not growth inhibited 
by trastuzumab are still responsive to trastuzumab. Specifically, we show that responsiveness to alternative HER-
targeted inhibitors, such as gefitinib and cetuximab, is dramatically potentiated by long-term trastuzumab treatment of 
ovarian cancer cells. HER2-positive ovarian carcinoma-derived cells are, therefore, not "unresponsive" to trastuzumab as 
previously assumed, even when they not growth inhibited by this drug.
Conclusions: Given the recent success of EGFR-targeted therapeutics for the treatment of other solid tumors, and the 
well-established safety profile of trastuzumab, results presented here provide a rationale for re-evaluation of 
trastuzumab as an experimental ovarian cancer therapeutic, either in concert with, or perhaps as a "primer" for EGFR-
targeted therapeutics.
Background
Cancer diagnostics and treatment are being revolution-
ized by the clinical application of information generated
during the past three decades of basic cancer research.
Some of the most difficult to treat malignancies have
been shown to have predictable alterations in key signal
transduction pathways, and the discovery of these abnor-
malities has allowed the development of improved, side-
effect sparing biologically-targeted therapeutics. Exam-
ples of these novel drugs include imatinib (Gleevec), tras-
tuzumab (Herceptin), gefitinib (Iressa) and erlotinib
(Tarceva), cetuximab (Erbitux) and panitumumab
(Vectibix), and sunitinib (Sutent), which have been FDA
approved for the treatment of chronic myelogenous leu-
kemia, HER2-positive breast cancer, non-small cell lung
cancer, colorectal cancer, and gastrointestinal stromal
and advanced kidney cancer, respectively. Each of these
drugs targets the specific kinase machinery on which
tumor cell growth is dependent. Despite the impressive
responsiveness of certain types of cancers to these new
drugs, resistance to many of these new drugs remains a
serious clinical obstacle. Nowhere is this more evident
than in advanced epithelial ovarian cancer (EOC), the
leading cause of death in women with gynecological
malignancies in the United States [1], for which only
incremental improvements in chemotherapy have been
achieved over the past several decades [2].
No biologically-targeted drugs have been approved for
the treatment of EOC. This is despite the observation
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that many candidate signaling proteins, including recep-
tor tyrosine kinases of the EGFR/ErbB/HER family, are
frequently expressed in these tumors. The EGFR/ErbB/
HER family of receptor tyrosine kinases (i.e., ErbB1/
HER1/EGFR, ErbB2/HER2/neu, ErbB3/HER3, ErbB4/
HER4) has been documented to play fundamental roles in
normal ovarian development, follicle maturation, ovula-
tion, and tissue homeostasis [3]. It is, therefore, not sur-
prising that overexpression of HER family members is
common in ovarian tumors and ovarian carcinoma-
derived cell lines. Yet, recent clinical trials targeting
EGFR with cetuximab [4-6], matuzumab [7], gefitinib [8],
and erlotinib [9] in EOC patients have shown only mod-
est clinical responsiveness http://www.gog.org.
Perhaps most surprising is the failure of HER2-targeted
therapeutics in the treatment of ovarian cancer patients.
Trastuzumab (Herceptin) is a therapeutic antibody that
targets HER2; it is a well-tolerated drug [10] and has
proven exceptionally useful in the treatment of HER2-
positive breast cancer [11]. A small number of early clini-
cal trials suggested that trastuzumab would not be an
effective treatment option for EOC patients [12,13],
despite the negative correlation between HER2 expres-
sion and survival in EOC patients [14]. Consequently,
trastuzumab use, even for further clinical study, has
quickly lost favor as an experimental therapeutic for the
treatment of ovarian cancer patients.
We and others previously have demonstrated that HER
receptor tumor cell expression, as currently measured, is
not an accurate positive predictor of responsiveness to
HER-targeted therapeutics [5,9,15]. Here we further
demonstrate that growth inhibition of ovarian cancer
cells is not an accurate metric of HER-targeted drug
"responsiveness." Specifically, we demonstrate that long-
term trastuzumab treatment of HER2-positive EOC-
derived cells confers de novo sensitivity to EGFR-targeted
therapeutics, regardless of trastuzumab's ability to inhibit
cell growth. We propose these results warrant re-evalua-
tion of the very definition of "trastuzumab resistance."
Moreover, since so-called 'resistant' EOC cells are, in fact,
primed by trastuzumab to acquire de novo sensitivity to
other HER-targeted therapeutics, we propose that these
results provide the rationale for re-evaluation of trastu-
zumab as an experimental ovarian cancer therapeutic,
perhaps as a priming agent for EGFR-targeted drugs.
Methods
Reagents and cell lines
Ovarian carcinoma cell lines A1847, A2780 (and cispla-
tin-resistant subclones A2780 CP30 and A2780 CP70),
BG-1, ES-2, MDAH-2774, OVCAR-7, OVCAR-10, PEO-
1, PEO-4, and UPN-251 were a obtained from Dr. D.
Connolly, OVCA-429, OVCA-432, and OVCA-433 were
obtained from Dr. R. Bast, Jr., IGROV-1 and OVCAR-8
were obtained from Dr. W . Cliby, SKOV-6 and SKOV-8
were a obtained from Dr. C. Marth, and the HEY cell line
w a s  o b t a i n e d  f r o m  D r .  R .  B u i c k .  O V C A R - 3 ,  a n d  t h e
breast carcinoma cell lines BT-474 and SKBR-3 were pur-
chased from the American Tissue Culture Collection.
Chinese hamster ovary (CHO) cells stably expressing
exogenous HER2 under the CMV promoter (CHO-
H E R 2 )  w e r e  e s t a b l i s h e d  b y  D r s .  H .  J .  L e e  a n d  M a i h l e
(unpublished result). Anti-EGFR (sc-03), anti-HER3 (sc-
285), and anti-HER4 (sc-283) antibodies were purchased
from Santa Cruz Biotechnologies. Anti-HER2 (Ab-1)
antibody was purchased from NeoMarkers, Inc. Func-
tion-blocking anti-HER3 antibody (H3.105) was pur-
chased from Upstate Biologicals. Anti-β-tubulin antibody
was purchased from Cell Signaling Technology. Cell cul-
ture media and all culture supplements were purchased
from Mediatech, except for fetal bovine serum (FBS),
which was purchased from Atlanta Biologicals, and G418,
which was purchased from GibcoBRL. Cetuximab was
obtained from Bristol Myers Squibb, trastuzumab was
obtained from Genentech, and erlotinib, gefitinib, and
lapatinib were obtained from Chemitek. Bovine serum
albumin, fraction V (BSA) and human transferrin were
purchased from Sigma-Aldrich. A colormetric WST-1-
based cell proliferation assay was purchased from Roche
Diagnostics.
Cell culture
All media formulations were supplemented with 10%
FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, and 2
mM L-glutamine. A1847, A2780, OVCAR-3, OVCAR-7,
OVCAR-10, PEO-1, PEO4, and UPN-251 were cultured
with RPMI 1640. BG-1 and HEY cells were cultured with
DMEM/Ham's F12. CAOV-3, IGROV-1, MDAH-2774,
OVCAR-5, OVCAR-8, and SKBR-3 cells were cultured
with DMEM. ES-2 and SKOV-3 cells were cultured with
McCoy's 5A. BT-474, OVCA-429, OVCA-432, OVCA-
433, SKOV-3, and SKOV-6 cells were cultured with
Eagle's MEM supplemented with 1 mM sodium pyruvate
and non-essential amino acids. CHO-HER2 were cul-
tured with Ham's F12, supplemented with 800 μg/ml
G418.
Immunoblot analysis of HER expression
Confluent or near-confluent dishes of cells were rinsed
with phosphate buffer (PBS; 4°C) and harvested by cell
scraping, followed by resuspension with PBS (4°C) and
brief centrifugation. Cell pellets were lysed by boiling
with 2.5% SDS, 0.5% sodium deoxycholate, and 0.5% NP-
40 for 10 minutes. Protein concentrations in cell lysates
were determined using the Bio-Rad DC assay. Cell
lysates, normalized by protein content, were resolved by
7.5% polyacrylamide gel electrophoresis in the presence
of 0.1% SDS. Gel proteins were transferred to polyvinylWilken et al. Journal of Ovarian Research 2010, 3:7
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difluoride membrane by semi-dry immunoblot (Milli-
pore), followed by blocking with TBS (10 mM Tris HCl,
150 mM NaCl, pH 7.4) prepared with 5% non-fat dry milk
for one hour at room temperature. Membranes were
rinsed six times for five minutes each with TBS with 0.1%
Tween 20 (TBS-TW20), and incubated with TBS with 1%
BSA and primary anti-EGFR (1:500 dilution), anti-HER2
(1:4000 dilution), anti-HER3 (1:250 dilution), or anti-
HER4 (1:500 dilution) overnight at 4°C. Membranes were
rinsed six times for ten minutes each with TBS-TW20
and incubated with goat anti-rabbit horseradish peroxi-
dase conjugated secondary antibody (Pierce, 1:4000 dilu-
tion) for one hour at room temperature. Membranes were
rinsed six times for ten minutes each, and chemilumi-
nescnce was visualized with a NucleoVISION camera sta-
tion following incubation with enhanced
chemiluminescent (ECL) reagent (Pierce).
Long-term trastuzumab treatment of ovarian cell lines
A1847, IGROV-1, OVCAR-7, and SKOV-3 cells were cul-
tured with (T100) or without (parental) 100 μg/ml trastu-
zumab for 12 weeks in RPMI 1610 media, supplemented
with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomy-
cin, 2 mM L-glutamine, and 1 mM sodium pyruvate.
Confluent or near-confluent flasks of cells were passaged
by treatment with 0.25% trypsin, and cells were resus-
pended and transferred to a new flask at a 1:10 dilution.
Effect of HER inhibitors on ovarian cell line growth
Parental and T100 A1847, IGROV-1, OVCAR-7, and
SKOV-3 cells were seeded into 96 well plates at a concen-
tration of 2.5 × 103 cells/50 μl of assay medium consisting
of RMPI 1610 media supplemented with penicillin/strep-
tomycin, L-glutamine, sodium pyruvate, 0.02% BSA, and
10 μg/ml human transferrin (assay media). After over-
n i g h t  i n c u b a t i o n  i n  s e r u m  f r e e  m e d i a ,  5 0  μ l  o f  a s s a y
media supplemented with 10% FBS, and either 2 μM gefi-
tinib, 2 μM erlotinib, 2 μM lapatinib, 400 μg/ml cetux-
imab, or 20 μg/ml H3.105 was added to each well in
quintuplicate. Cell proliferation was measured after 120
hours using a colormetric WST-1-based assay (n = 1).
Results
HER2-expression in EOC-derived cell lines is not correlated 
with trastuzumab mediated growth inhibition
HER2 expression was assayed in a large panel of EOC-
derived cell lines. As shown in Figure 1, the cell lines
SKOV-3 and OVCAR-7 expressed the highest levels of
HER2, whereas A1847 and IGROV-1 expressed moderate
levels of HER2. IGROV-1 and SKOV-3 both have been
reported previously to express moderate to high levels of
HER2, respectively [3], while HER2 expression in A1847
and OVCAR-7 has not been reported previously.
To determine whether HER2 expression might be cor-
related with trastuzumab sensitivity, the A1847, IGROV-
1, OVCAR-7, and SKOV-3 cell lines were treated with
increasing doses of trastuzumab in a cell proliferation
assay. As shown in Figure 2, A1847 was modestly growth
inhibited by trastuzumab, whereas IGROV-1, OVCAR-7,
and SKOV-3 were not growth inhibited, despite the wide
range of HER2 expression levels among this subset of cell
lines. In agreement with previous reports [16,17], SKBR-
3, a HER2-overexpressing breast-cancer cell line,
included here as a positive control, was growth inhibited
by trastuzumab (Fig. 2). In addition, the well-studied
HER2-positive breast cancer cell line BT-474 was >50%
growth inhibited by 10 μg/ml trastuzumab (data not
shown). Notably, CHO cells stably expressing exogenous
HER2 (CHO-HER2), but which express no other endoge-
nous HER family member, also were not growth inhibited
by trastuzumab (Fig. 2). We, therefore, conclude that tras-
tuzumab-mediated growth inhibition is not strictly corre-
lated with HER2 expression in the ovarian carcinoma-
derived cell lines studied in this panel. This counter-intu-
itive observation prompted us to evaluate whether long-
term trastuzumab treatment might have other measur-
able effects relevant to the expression and/or function of
related HER family members in these cell lines, as
described in greater detail below.
Long-term trastuzumab treatment induces moderate 
changes in HER expression
In an effort to model long-term trastuzumab treatment of
ovarian cancer in vitro, all four HER2-positive ovarian
cancer cell lines, i.e., A1847, IGROV-1, OVCAR-7, and
SKOV-3 were cultured continuously for 12 weeks in the
presence (T100) or absence (parental) of 100 μg/ml tras-
tuzumab, well within the range of serum trastuzumab
concentrations observed in EOC patients treated with
trastuzumab in a phase II clinical trial [12]. Lower trastu-
zumab concentrations were used for sensitive cell lines,
reaching 100 μg/ml by week six. Expression of all four
HER receptor family members was assessed in parental
vs. T100 cells by immunoblot analysis. In agreement with
previous reports, A1847 expressed moderate levels of
EGFR [18], IGROV-1 expressed moderate levels of both
EGFR and HER-2 [19], SKOV-3 expressed moderate lev-
els of EGFR, high HER-2, and low HER-3 and HER-4 [20].
Expression of HER-2, HER-3, and HER-4 in A1847, HER-
3 and HER-4 in IGROV-1, or any HER-family member in
OVCAR-7 has not been reported previously. Figure 3
illustrates the modest alteration of HER receptor expres-
sion in some T100 cells compared to parental cells; simi-
lar changes in the pattern of HER expression have been
reported in HER2-positive breast and mouse fibroblast
derived cell lines following treatment with trastuzumab
[15,21].Wilken et al. Journal of Ovarian Research 2010, 3:7
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Trastuzumab induces responsiveness to EGFR-targeted 
therapeutics
The observation that HER expression levels are variously
altered in T100 cells compared to parental cell lines led us
to hypothesize that T100 cells might also differ in their
growth-inhibitory response to HER-targeted inhibitors
relative to parental controls. All four T100 cell lines and
their corresponding parental counterparts were treated
with 1 μM gefitinib, 1 μM erlotinib, 1 μM lapatinib, or
200 μg/ml cetuximab for 120 hours; these concentrations
are at or below the steady-state peak serum concentra-
tions observed in treated cancer patients [22-25].
As summarized in Table 1, each of these FDA-approved
HER-targeted therapeutics effectively inhibited the
growth of certain T100 cells. For example, erlotinib and
lapatinib inhibited proliferation of all four tested cell
lines, whereas gefitinib inhibited the proliferation of
A1847 and SKOV-3 cells, and cetuximab inhibited the
proliferation of OVCAR-7 and SKOV-3. Furthermore,
subsets of T100 cells acquired de novo sensitivity to one
or more of these FDA-approved drugs: IGROV-1 T100
cells and OVCAR-7 T100 cells acquired de novo sensitiv-
ity to gefitinib, and IGROV-1 T100 cells and A1847 T100
Figure 1 Selection of HER2 positive ovarian carcinoma-derived cell lines. Cell lysates, normalized for protein content, were probed following 
SDS-PAGE with anti-HER2 and anti-EGFR antibody. A1847 and IGROV-1 cells, which express moderate levels of HER2, and OVCAR-7 and SKOV-3, which 
express high levels of HER2, were selected for further study. Cell lines selected for further study are noted with an asterisk. Tubulin expression is in-
cluded as a loading control. These blots are representative of two successive passages of ovarian carcinoma-derived cell lines.
Figure 2 Trastuzumab sensitivity does not correlate with HER2 
expression. A1847, IGROV-1, OVCAR-7, SKOV-3, SKBR-3, and CHO HER2 
cells were exposed to trastuzumab (0-75 μg/mL) for 120 hours, and cell 
proliferation was measured by a WST-1-based colormetric assay. 
A1847 and SKBR-3 cells were significantly growth inhibited by trastu-
zumab while IGROV-1, OVCAR-7, SKOV-3, and CHO HER2 cells were not 
significantly growth inhibited by trastuzumab. Student's T-test was 
used to determine whether significant differences in cell proliferation 
exist between untreated and treated cell populations. Asterisk denotes 
statistical variances (p < 0.05) where treated cells were growth inhibit-
ed.
Figure 3 HER expression reprogramming in ovarian carcinoma-
derived cell lines following long-term trastuzumab treatment. 
Immunoblot of epidermal growth factor receptor (EGFR), HER2, HER3, 
and HER4 expression in parental vs. T100 ovarian carcinoma cell lines 
A1847, IGROV-1, OVCAR-7, and SKOV-3. Lysates of parental and T100 
subclones, normalized for protein content, were probed following 
SDS-PAGE with α-EGFR, -HER2 -HER3, -HER4, and -tubulin. Note, en-
hanced chemiluminescent exposures were calibrated for each cell line 
to allow for accurate assessment of individual HER receptors; the HER 
expression patterns presented here are therefore not comparable be-
tween lanes.Wilken et al. Journal of Ovarian Research 2010, 3:7
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cells acquired de novo sensitivity to cetuximab (Table 1;
values in bold).
Discussion
One assumption underlying the advent of 'personalized
medicine' has been the concept of assessing the molecu-
lar characteristics of a patient's tumor in order to individ-
ually tailor a 'personalized' treatment strategy. Yet we and
others clearly show that identification of a specific target
molecule within a cell doesn't always correlate with suc-
cessful cell growth inhibition by biologically-targeted
therapeutics (e.g., CHO cells engineered to express HER2
are uneffected by trastuzumab treatment; Fig 2). Recent
results across disease sites further suggest that it may be
time to not only re-evaluate the accuracy of target gene
expression assays, but also the potential importance of
target gene expression itself in forecasting responsiveness
to certain biologically-targeted therapeutics. The recent
incongruity observed among EGFR-expressing colon
cancer patients and responsiveness to cetuximab is a case
in point. In these studies, K-Ras mutation status has
proven to be a clinically useful negative  indicator of
responsiveness to cetuximab [26-29], but in no case is
there a single accurate positive predictor of responsive-
ness to this new drug, including analysis of expression of
cetuximab's target i.e., EGFR, using currently available
methods. K-Ras, PTEN, c-Met, and mutations in the
EGFR tyrosine kinase domain, but not overall EGFR
expression, are associated with resistance to EGFR
tyrosine kinase inhibitors erlotinib and gefitinib in lung
cancer, as reviewed in [30,31]. More recently, Matulonis
and colleagues demonstrated that tumor HER3 expres-
sion is a better predictor than HER2 for response to per-
tuzumab (a HER2-directed therapeutic antibody) in
Table 1: HER inhibitors and cell proliferation in parental vs. T100 ovarian cell lines.
A1847 IGROV-1 OVCAR-7 SKOV-3
Parental T100 Parental T100 Parental T100 Parental T100
Gefitinib
0 μM 1.000 ± 0.055 1.000 ± 0.008 1.000 ± 0.017 1.000 ± 0.057 1.000 ± 0.010 1.000 ± 0.034 1.000 ± 0.008 1.000 ± 0.002
1 μM 0.812 ± 0.006 0.829 ± 0.040 0.998 ± 
0.039
0.691 ± 
0.026
0.977 ± 
0.125
0.899 ± 
0.060
0.797 ± 0.060 0.884 ± 0.022
p = 0.001 p = 0.0005 p = 0.93 p = 0.0006 p = 0.96 p = 0.02 p = 0.001 p = 0.0002
Erlotinib
0 μM 1.000 ± 0.075 1.000 ± 0.011 1.000 ± 0.041 1.000 ± 0.037 1.000 ± 0.072 1.000 ± 0.013 1.000 ± 0.027 1.000 ± 0.043
1 μM 0.741 ± 0.063 0.676 ± 0.053 0.753 ± 0.060 0.588 ± 0.046 0.612 ± 0.027 0.653 ± 0.096 0.625 ± 0.031 0.696 ± 0.023
p = 0.0004 p < 10-4 p = 0.001 p < 10-6 p = 0.0007 p = 0.001 p = 10-6 p < 10-27
Lapatinib
0 μM 1.000 ± 0.007 1.000 ± 0.027 1.000 ± 0.048 1.000 ± 0.062 1.000 ± 0.070 1.000 ± 0.023 1.000 ± 0.108 1.000 ± 0.047
1 μM 0.762 ± 0.063 0.645 ± 0.069 0.789 ± 0.098 0.666 ± 0.031 0.819 ± 0.084 0.673 ± 0.048 0.845 ± 0.023 0.889 ± 0.082
p = 0.001 p = 0.0001 p = 0.005 p < 10-4 p = 0.006 p < 10-5 p = 0.03 p = 0.04
Cetuximab
0 μg/ml 1.000 ± 0.091 1.000 ± 0.038 1.000 ± 0.075 1.000 ± 0.067 1.000 ± 0.090 1.000 ± 0.032 1.000 ± 0.031 1.000 ± 0.049
200 μg/ml 0.974 ± 
0.027
0.594 ± 
0.110
0.892 ± 
0.071
0.554 ± 
0.067
0.588 ± 0.050 0.657 ± 0.057 0.736 ± 0.038 0.854 ± 0.010
p = 0.57 p = 0.0006 p = 0.07 p < 10-5 p < 10-4 p < 10-4 p < 10-5 p = 0.002
H3.105
0 μg/ml 1.000 ± 0.071 1.000 ± 0.022 1.000 ± 0.050 1.000 ± 0.050 1.000 ± 0.011 1.000 ± 0.028 1.000 ± 0.040 1.000 ± 0.018
10 μg/ml 0.913 ± 0.095 0.989 ± 0.059 1.006 ± 0.132 0.979 ± 0.152 0.895 ± 0.030 0.856 ± 0.027 0.969 ± 0.039 1.048 ± 0.043
p = 0.14 p = 0.71 p = 0.92 p = 0.78 p = 0.0006 p < 10-4 p = 0.28 p = 0.07
Parental vs. long-term trastuzumab treated (T100) A1847, IGROV-1, OVCAR-7, and SKOV-3 cells were treated with gefitinib, erlotinib, lapatinib, 
cetuximab, or H3.105 for 120 hours, and cell proliferation was measured by a WST-1-based colormetric assay. The inter-quartile rule was used 
to eliminate data outliers before calculating the mean absorbance for untreated and treated cell populations. Fold change in cell numbers is 
normalized against values determined for untreated cells. Student's T-test was used to calculate p values. Instances where T100 but not 
parental cell lines were significantly growth inhibited are highlighted in bold.Wilken et al. Journal of Ovarian Research 2010, 3:7
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patients with platinum-resistant ovarian cancer [32].
Even in the well studied case of breast cancer, Paik et al.,
have shown that patients with tumors expressing even
low levels of HER2 may gain benefit from trastuzumab
therapy [33]. Together, these results are consistent with
the notion that analysis of signaling networks and their
aberrations may be better predictors of therapeutic
response than is analysis of individual components within
these networks.
In the case of EOC, for example, trastuzumab has not
been shown to be effective in early clinical trials for the
treatment of ovarian cancer patients. These disappoint-
ing results have been vexing since EOC tumors and EOC-
derived cell lines express or overexpress HER family
members at the same frequency as do many malignant
breast tumors. Yet, if one examines the in vitro effects of
trastuzumab, such results may be less surprising. For
example, trastuzumab does not inhibit Akt activity in the
ovarian carcinoma-derived cell line SKOV-3 [34] despite
similar levels of HER2 expression as those observed in the
breast carcinoma cell line SKBR-3 in which trastuzumab
is a potent cell growth inhibitor [35]. Based on these
results, we and others have proposed that comprehensive
analysis of expression of all four HER family members,
and their isoforms, as well as key components of their sig-
naling networks may be necessary to improve the positive
predictive value of these theragnostic and prognostic bio-
marker assays [3,32,36].
In this study we show that trastuzumab treatment
results in the acquisition of de novo sensitivity to gefitinib
or cetuximab in three of four EOC cell lines tested, imply-
ing that HER2 signaling is dispensable in these cells con-
comitant with compensatory EGFR signaling. While we
note that HER2 expression was decreased in all three cell
lines which acquired de novo drug sensitivity (T100
cells), the small number of cell lines used and single time
point tested prevent us from concluding that HER2
downregulation is the mechanism of trastuzumab 'prim-
ing'. It is interesting to note, however, that complemen-
tary observations have been made in prostate cancer;
gefitinib treatment of the prostate cancer cell line 22Rv1
sensitizes cells to the HER2-targeted antibody pertu-
zumab [37].
Our study also further highlights the differences
observed between breast and ovarian cancer responsive-
ness to trastuzumab. Such differences are perhaps not
surprising given that the progenitors of mesodermally-
derived ovarian surface epithelial cells vs. ectodermally-
derived breast (ductal) epithelial cells diverge early during
embryonic gastrulation. It is, therefore, likely that the
growth regulatory roles of HER2, as well as other HER
family receptors, are divergent in these two tissues. Such
functional differences may be reflected in the empirical
differences observed between these tumors, such as the
higher frequency of HER2 gene amplification in breast vs.
EOC tumors [38]. In this context, while it is possible that
long-term trastuzumab treatment results in the selection
of resistant ovarian cancer subclones, we favor the
hypothesis that long-term trastuzumab treatment may
restrict generation-to-generation heritability of protein
expression, a phenomenon recently described by Spencer
et al. as a non-genetic mechanism underlying tumor het-
erogeneity in response to targeted therapeutics [39].
Moreover, a number of studies have demonstrated that
in some HER2-positive breast carcinoma-derived cell
lines, trastuzumab treatment may not directly inhibit cell
growth, but still results in latent but important pheno-
types. For example, the HER2-positive breast cell line
JIMT-1 in vitro and in xenograft models is not signifi-
cantly growth inhibited by trastuzumab [40]; however,
trastuzumab does inhibit establishment of distant metas-
tases [41]. The clinical importance of this observation is
underscored by a recent study demonstrating that trastu-
zumab continues to improve survival even in patients
who have developed apparently trastuzumab "resistant"
disease [42]. In addition, other studies have demonstrated
that trastuzumab sensitizes HER2-positive breast cell
lines to ionizing radiation [43] and all-trans retinoic acid
[44] without directly affecting cell proliferation.
In further support of this concept, our results suggest
that in EOC, HER2 may potentiate but not be required
for tumor cell growth, at least in a majority of cases. In
the context of current terminology, this observation sug-
gests that HER2 may not be an "addictive" oncogene in
EOC [45], consistent with the prediction of Sharma and
Settleman regarding 'oncogenic shock' [46,47]. The onco-
genic shock hypothesis proposes that apoptosis following
inhibition of an oncogene is caused by the rapid cessation
of survival and growth signals with concurrent persis-
tence of longer-lasting apoptotic signals. Our observa-
tions suggest that inhibition of a "dispensable" regulator
of cell growth (in this case, HER2 in EOC) could increase
reliance on another oncogene (EGFR) which, upon inhi-
bition, could initiate oncogenic shock. In this context,
one could envision a therapeutic strategy in which a
tumor is "tricked" by one drug into (obligate) reliance on
growth and/or survival pathways that could then be
halted by a second drug. A parallel strategy has been sug-
gested by Cao et al., wherein a signaling pathway (i.e.,
EGFR) is simultaneously stimulated with ligand and
blocked with a specific kinase inhibitor, thereby downreg-
ulating the receptor without inducing mitogenic or sur-
vival signaling [48].
Finally, while the limited number of cell lines used in
this study is insufficient to conclude that the basis for the
development of de novo sensitivity to HER-targeted
inhibitors is the induction of EGFR/HER3 expression by
trastuzumab, here we propose that these results shouldWilken et al. Journal of Ovarian Research 2010, 3:7
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Page 7 of 9
be considered in the design of future ovarian cancer clini-
cal trials. To be useful clinically, the phenomena
described here must first be better understood in the
patient, and particularly the kinetics of these phenomena.
In the present study, the 12-week trastuzumab time
course was chosen to mimic the treatment regimen of a
patient who proved resistant or refractory to trastuzumab
monotherapy. It may be possible to design future clinical
trials to determine both the time course of changes in
HER receptor expression in vivo, and/or the clinical feasi-
bility (and kinetics) of trastuzumab "priming."
Conclusions
In conclusion, it is possible that the disappointing results
of clinical targeting of the HER axis in EOC patients
stems from the intuitive, but perhaps incorrect assump-
tion that there is a correlation between HER2 expression
and responsiveness to trastuzumab. This point is sup-
ported by one recent breast cancer study which found no
direct correlation between HER2 expression levels and
benefit from trastuzumab therapy [33]. Similarly, there is
one intriguing case report which describes remission of a
patient with HER2-negative, invasive EOC following tras-
tuzumab treatment [49]. Together, these observations
suggest that ovarian cancer patients whose tumor cells
express reduced, and perhaps even undetectable levels of
HER2 as assessed by today's diagnostic standards, may
benefit from trastuzumab "priming." Our results further
indicate that SKOV-3 may not be the most representative
ovarian carcinoma-derived cell line for future preclinical
studies of trastuzumab in EOC, despite the historic, and
nearly exclusive use of this cell line as a model for EOC in
previous preclinical studies on trastuzumab [34,50-60]. In
light of these new results and our improved understand-
ing of trastuzumab's myriad effects on ovarian cancer
cells, further studies to evaluate the potential clinical util-
ity of trastuzumab in ovarian cancer patients are clearly
warranted.
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